{"id":"https://openalex.org/W7222913249","doi":"https://doi.org/10.64898/2026.10.16.26364955","title":"Pharmacovigilance and Mechanistic Analysis of Adverse Reaction Differences Across EGFR Tyrosine Kinase Inhibitor Generations in Non-Small Cell Lung Cancer","display_name":"Pharmacovigilance and Mechanistic Analysis of Adverse Reaction Differences Across EGFR Tyrosine Kinase Inhibitor Generations in Non-Small Cell Lung Cancer","publication_year":2026,"publication_date":"2026-10-19","ids":{"openalex":"https://openalex.org/W7222913249","doi":"https://doi.org/10.64898/2026.10.16.26364955"},"language":"en","primary_location":{"id":"doi:10.64898/2026.10.16.26364955","doi":"https://doi.org/10.64898/2026.10.16.26364955","is_oa":true,"landing_page_url":"https://doi.org/10.64898/2026.10.16.26364955","pdf_url":"https://www.medrxiv.org/content/medrxiv/early/2026/10/19/2026.10.16.26364955.full.pdf","source":{"id":"https://openalex.org/S3005729997","display_name":"medRxiv","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":["https://openalex.org/P4310315909"],"host_organization_lineage_names":["Cold Spring Harbor Laboratory Press"],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"medRxiv","raw_type":"posted-content"},"volume":null,"type":"preprint","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.medrxiv.org/content/medrxiv/early/2026/10/19/2026.10.16.26364955.full.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5159002734","display_name":"Oluwadamilola Arojo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I79619799","display_name":"University of Birmingham","ror":"https://ror.org/03angcq70","country_code":"GB","type":"education","lineage":["https://openalex.org/I79619799"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Oluwadamilola Arojo","raw_affiliation_strings":["School of Pharmacy, University of Birmingham, Edgbaston, B15 2TT, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Pharmacy, University of Birmingham, Edgbaston, B15 2TT, United Kingdom","institution_ids":["https://openalex.org/I79619799"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5021438499","display_name":"Alan M. Jones","orcid":"https://orcid.org/0000-0002-3897-5626","observed_orcids":["https://orcid.org/0000-0002-3897-5626"]},"institutions":[{"id":"https://openalex.org/I79619799","display_name":"University of Birmingham","ror":"https://ror.org/03angcq70","country_code":"GB","type":"education","lineage":["https://openalex.org/I79619799"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Alan M. Jones","raw_affiliation_strings":["School of Pharmacy, University of Birmingham, Edgbaston, B15 2TT, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0002-3897-5626","affiliations":[{"raw_affiliation_string":"School of Pharmacy, University of Birmingham, Edgbaston, B15 2TT, United Kingdom","institution_ids":["https://openalex.org/I79619799"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5021438499"],"corresponding_institution_ids":["https://openalex.org/I79619799"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.5776000022888184,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.5776000022888184,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.4162999987602234,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.996999979019165},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.890999972820282},{"id":"https://openalex.org/keywords/egfr-mutant-non-small-cell-lung-cancer","display_name":"EGFR-mutant non-small cell lung cancer","score":0.8090000152587891},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.9779999852180481},{"id":"https://openalex.org/keywords/pharmacovigilance","display_name":"pharmacovigilance","score":0.9340000152587891},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.9490000009536743},{"id":"https://openalex.org/keywords/afatinib","display_name":"afatinib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/osimertinib","display_name":"osimertinib","score":1.0},{"id":"https://openalex.org/keywords/eye-diseases","display_name":"eye diseases","score":0.5920000076293945},{"id":"https://openalex.org/keywords/pneumonitis","display_name":"pneumonitis","score":0.9419999718666077},{"id":"https://openalex.org/keywords/pulmonary-embolism","display_name":"pulmonary embolism","score":0.9010000228881836},{"id":"https://openalex.org/keywords/mental-disorders","display_name":"mental illness","score":0.8700000047683716},{"id":"https://openalex.org/keywords/diarrhea","display_name":"diarrhea","score":0.8619999885559082},{"id":"https://openalex.org/keywords/drug-safety-signals","display_name":"drug safety signals","score":0.46799999475479126},{"id":"https://openalex.org/keywords/mechanistic-analysis","display_name":"mechanistic analysis","score":0.4699999988079071},{"id":"https://openalex.org/keywords/pharmacokinetic-properties","display_name":"pharmacokinetic properties","score":0.4779999852180481}],"concepts":[{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.676800012588501},{"id":"https://openalex.org/C57658597","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Pharmacovigilance","level":3,"score":0.6280999779701233},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.6194000244140625},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5849999785423279},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5788000226020813},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.5170999765396118},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.4323999881744385},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.413100004196167},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.4074000120162964},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4018000066280365},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.34040001034736633},{"id":"https://openalex.org/C2909867262","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Protein-Tyrosine Kinases","level":4,"score":0.3312999904155731},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.3255000114440918},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3246999979019165},{"id":"https://openalex.org/C2780542314","wikidata":"https://www.wikidata.org/wiki/Q45959","display_name":"Adverse drug reaction","level":3,"score":0.3244999945163727},{"id":"https://openalex.org/C2778347629","wikidata":"https://www.wikidata.org/wiki/Q4652380","display_name":"ALK inhibitor","level":5,"score":0.3093999922275543},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.29789999127388},{"id":"https://openalex.org/C169382597","wikidata":"https://www.wikidata.org/wiki/Q21208025","display_name":"Programmed cell death 1","level":5,"score":0.29760000109672546},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.2849999964237213},{"id":"https://openalex.org/C2776980637","wikidata":"https://www.wikidata.org/wiki/Q427492","display_name":"Enzyme inhibitor","level":3,"score":0.2784999907016754},{"id":"https://openalex.org/C2911166042","wikidata":"https://www.wikidata.org/wiki/Q420511","display_name":"Receptor Protein-Tyrosine Kinases","level":4,"score":0.27649998664855957},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.2734000086784363},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.25450000166893005},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.2535000145435333}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.64898/2026.10.16.26364955","doi":"https://doi.org/10.64898/2026.10.16.26364955","is_oa":true,"landing_page_url":"https://doi.org/10.64898/2026.10.16.26364955","pdf_url":"https://www.medrxiv.org/content/medrxiv/early/2026/10/19/2026.10.16.26364955.full.pdf","source":{"id":"https://openalex.org/S3005729997","display_name":"medRxiv","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":["https://openalex.org/P4310315909"],"host_organization_lineage_names":["Cold Spring Harbor Laboratory Press"],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"medRxiv","raw_type":"posted-content"},{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/6b4ec287-58a4-4d5c-86d1-4dcaded645ed","doi":null,"is_oa":true,"landing_page_url":"https://research.birmingham.ac.uk/en/publications/6b4ec287-58a4-4d5c-86d1-4dcaded645ed","pdf_url":null,"source":{"id":"https://openalex.org/S4306402634","display_name":"University of Birmingham Research Portal (University of Birmingham)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I79619799","host_organization_name":"University of Birmingham","host_organization_lineage":["https://openalex.org/I79619799"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Arojo, O & Jones, A M 2026 'Pharmacovigilance and Mechanistic Analysis of Adverse Reaction Differences Across EGFR Tyrosine Kinase Inhibitor Generations in Non-Small Cell Lung Cancer' medRxiv. https://doi.org/10.64898/2026.10.16.26364955","raw_type":"info:eu-repo/semantics/preprint"}],"best_oa_location":{"id":"doi:10.64898/2026.10.16.26364955","doi":"https://doi.org/10.64898/2026.10.16.26364955","is_oa":true,"landing_page_url":"https://doi.org/10.64898/2026.10.16.26364955","pdf_url":"https://www.medrxiv.org/content/medrxiv/early/2026/10/19/2026.10.16.26364955.full.pdf","source":{"id":"https://openalex.org/S3005729997","display_name":"medRxiv","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":["https://openalex.org/P4310315909"],"host_organization_lineage_names":["Cold Spring Harbor Laboratory Press"],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"medRxiv","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7222913249.pdf","grobid_xml":"https://content.openalex.org/works/W7222913249.grobid-xml"},"referenced_works_count":37,"referenced_works":["https://openalex.org/W1499416822","https://openalex.org/W1840732701","https://openalex.org/W1977161245","https://openalex.org/W1979832276","https://openalex.org/W2021548877","https://openalex.org/W2054841768","https://openalex.org/W2086049425","https://openalex.org/W2144001833","https://openalex.org/W2281073143","https://openalex.org/W2484071785","https://openalex.org/W2615601352","https://openalex.org/W2743559198","https://openalex.org/W2755766815","https://openalex.org/W2760475378","https://openalex.org/W2935991996","https://openalex.org/W2996304730","https://openalex.org/W2997396703","https://openalex.org/W3011413299","https://openalex.org/W3042182682","https://openalex.org/W3091781059","https://openalex.org/W3164407672","https://openalex.org/W3203034670","https://openalex.org/W4200350576","https://openalex.org/W4242648511","https://openalex.org/W4283796715","https://openalex.org/W4292647761","https://openalex.org/W4309162194","https://openalex.org/W4310796255","https://openalex.org/W4396696102","https://openalex.org/W4405193292","https://openalex.org/W4406778058","https://openalex.org/W4408314603","https://openalex.org/W4409382696","https://openalex.org/W4410100728","https://openalex.org/W4411075388","https://openalex.org/W4411627206","https://openalex.org/W4416667329"],"related_works":["https://openalex.org/W3011413299","https://openalex.org/W7147535635","https://openalex.org/W7154986079","https://openalex.org/W7202269387","https://openalex.org/W4408314603","https://openalex.org/W4414507756","https://openalex.org/W7115935678","https://openalex.org/W4400272481","https://openalex.org/W4401995886","https://openalex.org/W2562380622"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"Epidermal":[2],"Growth":[3],"Factor":[4],"Receptor":[5],"(EGFR)":[6],"tyrosine":[7],"kinase":[8,411],"inhibitors":[9],"(TKIs)":[10],"are":[11,219,245,252],"widely":[12],"used":[13,72],"for":[14,53,206,248,317,359,365,372],"EGFR-mutated":[15,249],"non-small":[16],"cell":[17],"lung":[18],"cancer":[19],"(NSCLC)":[20],"but":[21,251,299,425],"have":[22,294,304],"distinct":[23,255],"toxicity":[24],"profiles":[25,260],"across":[26,263,309],"generations.":[27,264],"Aims":[28],"To":[29],"investigate":[30],"relationships":[31],"between":[32],"EGFR-TKI":[33,296],"physicochemical,":[34],"pharmacokinetic":[35],"and":[36,39,47,56,67,88,99,112,130,166,182,221,243,271,313,334,363,367,369,387,409,428],"pharmacological":[37,315],"properties":[38,92,202],"drug-specific":[40],"adverse":[41,256],"drug":[42,201,257,439],"reactions":[43],"(ADRs)":[44],"using":[45,285,338],"national":[46],"global":[48],"pharmacovigilance":[49,197,283,394],"data.":[50],"Methods":[51],"ADRs":[52],"erlotinib,":[54],"afatinib":[55,212,242],"osimertinib":[57],"were":[58,78,93,126],"extracted":[59],"from":[60,95,423],"the":[61,146,210,286,314,393,443],"UK":[62],"MHRA":[63,331],"Yellow":[64,113,133,138,155,301,332],"Card":[65,114,139,156,302,333],"scheme":[66],"WHO":[68,335],"VigiAccess.":[69],"Disproportionality":[70],"analysis":[71,329],"reporting":[73,427],"odds":[74],"ratios":[75],"(RORs).":[76],"Signals":[77],"defined":[79],"as":[80,432],"ROR":[81,153,157],"\u22652,":[82],"lower":[83,346],"95%":[84,347],"confidence":[85],"interval":[86],">1":[87],"\u22653":[89],"cases.":[90],"Drug":[91],"curated":[94],"ChEMBL,":[96],"emc,":[97],"SmPC":[98],"EMA":[100],"sources.":[101],"Results":[102],"VigiAccess":[103,129,336],"contained":[104,115],"88,662":[105],"individual":[106],"case":[107],"safety":[108,297,440],"reports":[109,117],"(163,619":[110],"ADRs)":[111],"752":[116],"(1,814":[118],"ADRs).":[119],"Four":[120],"System":[121,292],"Organ":[122],"Class":[123],"(SOC)":[124],"signals":[125,175,187,395,422,441],"identified":[127,429],"in":[128,132,176,224,278,403,449],"three":[131,311],"Card,":[134],"with":[135,150,162,200,254,392],"five":[136],"additional":[137],"Preferred":[140],"Term":[141],"signals.":[142],"Eye":[143],"disorders":[144,358,362],"showed":[145,172],"strongest":[147],"consistent":[148],"association":[149,214],"erlotinib":[151],"(VigiAccess":[152],"4.33;":[154],"4.18).":[158],"Osimertinib":[159],"was":[160],"associated":[161,253],"pneumonitis":[163,368],"(ROR":[164,169,179,184,343],"7.67)":[165],"pulmonary":[167,370],"embolism":[168,371],"3.94).":[170],"Afatinib":[171],"psychiatric":[173,213,361],"disorder":[174],"both":[177],"databases":[178],"3.2\u2013":[180],"3.3)":[181],"diarrhoea":[183,364],"2.79).":[185],"Neoplasm-related":[186],"likely":[188],"reflected":[189],"confounding":[190],"by":[191,434],"indication.":[192],"Conclusions":[193],"EGFR-TKIs":[194,240],"demonstrate":[195],"generation-specific":[196,318,355],"profiles.":[198],"Integration":[199,374],"supports":[203],"mechanistic":[204,228,397],"plausibility":[205],"several":[207],"signals,":[208,298],"while":[209],"atypical":[211],"warrants":[215],"further":[216],"investigation.":[217],"Findings":[218],"hypothesis-generating":[220],"require":[222],"confirmation":[223],"controlled":[225],"observational":[226],"or":[227],"studies.":[229],"What":[230,323],"is":[231],"already":[232],"known":[233],"about":[234],"this":[235,324],"subject?":[236],"First-,":[237],"second-and":[238],"third-generation":[239],"(erlotinib,":[241],"osimertinib)":[244],"established":[246],"treatments":[247],"NSCLC":[250],"reaction":[258],"(ADR)":[259],"that":[261],"differ":[262],"Known":[265],"class-effect":[266],"toxicities":[267],"include":[268],"dermatological,":[269],"gastrointestinal,":[270],"ocular":[272],"ADRs,":[273],"attributed":[274],"to":[275,401],"EGFR":[276,407],"inhibition":[277],"non-tumour":[279],"epithelial":[280],"tissues.":[281],"Prior":[282],"studies":[284],"US":[287],"FDA":[288],"Adverse":[289],"Event":[290],"Reporting":[291],"(FAERS)":[293],"characterised":[295],"UK-specific":[300],"data":[303,391],"not":[305],"been":[306],"systematically":[307],"analysed":[308],"all":[310],"generations,":[312],"basis":[316],"differences":[319],"remains":[320],"incompletely":[321],"understood.":[322],"study":[325],"adds":[326],"Dual-database":[327],"disproportionality":[328],"of":[330,375,445],"data,":[337],"a":[339,414],"pre-specified":[340],"signal":[341,417,447],"threshold":[342,418],"\u2265":[344,352],"2,":[345],"CI":[348],">":[349],"1,":[350],"n":[351],"3),":[353],"confirmed":[354],"signals:":[356],"eye":[357],"erlotinib;":[360],"afatinib;":[366],"osimertinib.":[373],"target":[376],"potency":[377],"(pIC50),":[378],"ErbB":[379],"family":[380],"selectivity,":[381],"blood":[382],"brain":[383],"barrier":[384],"(BBB)":[385],"penetration":[386],"CYP":[388],"450":[389],"interaction":[390],"provides":[396],"plausibility,":[398],"linking":[399],"them":[400],"variations":[402],"binding":[404],"reversibility,":[405],"wild-type":[406],"inhibition,":[408],"off-target":[410],"activity.":[412],"Applying":[413],"pre-specified,":[415],"conservative":[416],"distinguished":[419],"genuine":[420],"disproportionate":[421],"elevated":[424],"non-significant":[426],"neoplasm-related":[430],"findings":[431],"confounded":[433],"indication":[435],"rather":[436],"than":[437],"true":[438],"highlighting":[442],"importance":[444],"rigorous":[446],"definition":[448],"oncology":[450],"pharmacovigilance.":[451]},"counts_by_year":[],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2026-10-19T00:00:00"}